BR112020000477A2 - ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer - Google Patents

ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer Download PDF

Info

Publication number
BR112020000477A2
BR112020000477A2 BR112020000477-4A BR112020000477A BR112020000477A2 BR 112020000477 A2 BR112020000477 A2 BR 112020000477A2 BR 112020000477 A BR112020000477 A BR 112020000477A BR 112020000477 A2 BR112020000477 A2 BR 112020000477A2
Authority
BR
Brazil
Prior art keywords
cells
sample
cell
cgamp
expression
Prior art date
Application number
BR112020000477-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Lewis C. Cantley
Bryan Ngo
Samuel F. BAKHOUM
Original Assignee
Cornell University
Memorial Sloan-Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University, Memorial Sloan-Kettering Cancer Center filed Critical Cornell University
Publication of BR112020000477A2 publication Critical patent/BR112020000477A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
BR112020000477-4A 2017-07-10 2018-07-10 ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer BR112020000477A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762530661P 2017-07-10 2017-07-10
US62/530,661 2017-07-10
PCT/US2018/041480 WO2019014246A1 (en) 2017-07-10 2018-07-10 TARGETING CHROMOSOMIC INSTABILITY AND SIGNALING OF CYTOSOLIC DNA IN AVAL FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
BR112020000477A2 true BR112020000477A2 (pt) 2020-07-21

Family

ID=63036469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020000477-4A BR112020000477A2 (pt) 2017-07-10 2018-07-10 ataque à instabilidade cromossômica e sinalização de dna citosólico a jusante para tratamento de câncer

Country Status (12)

Country Link
US (2) US11821042B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652349A1 (cg-RX-API-DMAC7.html)
JP (1) JP7197556B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200037796A (cg-RX-API-DMAC7.html)
CN (1) CN111295454A (cg-RX-API-DMAC7.html)
AU (1) AU2018300007A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000477A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069515A1 (cg-RX-API-DMAC7.html)
IL (1) IL271849A (cg-RX-API-DMAC7.html)
MX (1) MX2020000406A (cg-RX-API-DMAC7.html)
SG (1) SG11202000132WA (cg-RX-API-DMAC7.html)
WO (1) WO2019014246A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901393VA (en) * 2016-09-02 2019-03-28 Univ Illinois Kif13b-derived peptide and method of inhibiting angiogenesis
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment
JP7226763B2 (ja) * 2017-08-17 2023-02-21 国立大学法人山口大学 癌幹細胞における薬物耐性の低減剤、癌幹細胞における転移能の抑制剤及び癌の転移性再発リスクを予測する方法
US20230106899A1 (en) * 2019-06-21 2023-04-06 Ifm Due, Inc. Methods of treating cancer
WO2021167478A1 (en) * 2020-02-19 2021-08-26 Ibmc - Instituto De Biologia Molecular E Celular 4-pyrrolidin-1-yl-5-p-tolyl-thieno[2,3-d] pyrimidine for use in the treatment of aging-associated and premature aging diseases through restored chromosomal stability and inhibition of cellular senescence
CN112113821B (zh) * 2020-05-28 2021-09-03 王剑 一种细胞病理学样本的多重染色制片方法
WO2022051420A1 (en) * 2020-09-02 2022-03-10 Memorial Sloan Kettering Cancer Center Methods and compositions for targeting cytosolic dsdna signaling in chromosomally unstable cancers
US20240207248A1 (en) * 2021-04-23 2024-06-27 Baruch S. Blumberg Institute Methods, kits and compositions for reducing chromosomal instability in cancer cells
CN113341154B (zh) * 2021-05-14 2024-11-05 医工瑞思(福建)工程研究中心有限公司 一种检测血栓或凝血相关疾病的生物标志物及其应用
KR20240109977A (ko) 2021-08-26 2024-07-12 볼라스트라 쎄라퓨틱스, 인코포레이티드 Kif18a의 스피로 인돌린 억제제
CN115354078B (zh) * 2022-09-02 2023-07-07 中山大学附属第一医院 骨肉瘤检测标记物及其应用
EP4488389A1 (en) * 2023-07-05 2025-01-08 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Signature for the prognosis of brain metastasis relapse

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1994007529A1 (en) 1992-09-25 1994-04-14 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
JP2016506408A (ja) * 2012-12-19 2016-03-03 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化
EP3045917A2 (en) * 2013-09-13 2016-07-20 Sierra Jiménez, Angels Marker for predicting metastasis of breast cancer
SG10201807838SA (en) * 2014-03-11 2018-10-30 Council Queensland Inst Medical Res Determining cancer aggressiveness, prognosis and responsiveness to treatment
CN107106544B (zh) * 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
WO2016176222A1 (en) * 2015-04-30 2016-11-03 University Of Washington Cgas in systemic lupus erythematosus (sle)
US11821042B2 (en) 2017-07-10 2023-11-21 Cornell University Targeting chromosomal instability and downstream cytosolic DNA signaling for cancer treatment

Also Published As

Publication number Publication date
AU2018300007A1 (en) 2020-02-27
US20210130903A1 (en) 2021-05-06
US11821042B2 (en) 2023-11-21
US20240110246A1 (en) 2024-04-04
MX2020000406A (es) 2020-10-01
SG11202000132WA (en) 2020-02-27
JP7197556B2 (ja) 2022-12-27
IL271849A (en) 2020-02-27
CN111295454A (zh) 2020-06-16
WO2019014246A1 (en) 2019-01-17
CA3069515A1 (en) 2019-01-17
EP3652349A1 (en) 2020-05-20
JP2020526206A (ja) 2020-08-31
KR20200037796A (ko) 2020-04-09

Similar Documents

Publication Publication Date Title
US20240110246A1 (en) Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
US20230111697A1 (en) Methods for treating hair loss disorders
US11873486B2 (en) Modulating dsRNA editing, sensing, and metabolism to increase tumor immunity and improve the efficacy of cancer immunotherapy and/or modulators of intratumoral interferon
US20230203485A1 (en) Methods for modulating mhc-i expression and immunotherapy uses thereof
KR102135601B1 (ko) 탈모 질환의 치료 방법
US20190300967A1 (en) Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
US20230075965A1 (en) Uses of biomarkers for improving immunotherapy
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
CN113383085A (zh) 用于分析核酸分子的方法和系统
US20200108066A1 (en) Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
US11377697B2 (en) Biomarkers predictive of anti-immune checkpoint response
KR20160117606A (ko) 항-혈관형성 약물에 대한 반응 및 암의 예후를 예측하기 위한 분자적 진단 시험
US20230105008A1 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
CN110945030A (zh) 使用april-taci相互作用的调节剂调节调控性t细胞、调控性b细胞和免疫响应的方法
CN116583537A (zh) 与对过继细胞疗法的应答相关的t细胞表型
US20200300859A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
US20240280561A1 (en) Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP3743058A1 (en) Methods for predicting tumor response to immunotherapy
KR20240005018A (ko) 핵산 분자를 분석하기 위한 방법 및 시스템
CA3212132A1 (en) Methods of treating red blood cell disorders
US20260117178A1 (en) Means to treat autoimmunity by refining regulatory t cells
US12480163B2 (en) Compositions and methods for identification assessment, prevention, and treatment of Ewing sarcoma using TP53 dependency biomarkers and modulators
US20220298580A1 (en) Immune signatures predictive of response to pd-1 blockade in richter's transformation
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy
HK40060652A (en) Methods and systems for analyzing nucleic acid molecules

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements